Live Breaking News & Updates on Lars Erik Kristensen

Stay updated with breaking news from Lars erik kristensen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Long COVID and Patients with Rheumatic Disease: Perspective from EULAR 2023

A group of rheumatologists attending EULAR 2023 provide perspective on their concern regarding the potential threat posed by long COVID in patients with rheumatic disease. ....

George Karpouzas , Brian Lamoreaux , Lars Erik Kristensen , R George Karpouzas , Cozianna Ciurtin , Coziana Ciurtin , University College London , Global Rheumatology Alliance Vaccine , Parker Institute , Division Of Rheumatology At , United Nations , David Geffen School Of Medicine , Lunquist Institute , European Congress , World Health Organization , Rheumatology Alliance Vaccine Survey , David Geffen School , Horizon Therapeutics , Rheumatology Alliance Vaccine ,

Risankizumab Provides Durable Quality of Life Improvements out to 100 Weeks in Psoriatic Arthritis

An analysis of 100 week data from the KEEPsAKE 1 and 2 trials presented at EULAR 2023 offers insight into the long-term effects of risankizumab use in people with psoriatic arthritis. ....

Lars Erik Kristensen , Eli Lilly , Parker Institute , European Congress , Bristol Myers Squibb , European Congress On Rheumatology , Ann Rheum ,

Smoking, older age put patients receiving tofacitinib at higher risk for MACE vs. TNFi

Patients aged 65 years and older or who have ever smoked are at higher risk for malignancies, major adverse cardiovascular events, myocardial infarction and all-cause death when using tofacitinib vs. TNF inhibitors, according to data. Meanwhile, patients aged younger than 65 years who have never smoked demonstrated no apparent increased risk when receiving tofacitinib (Xeljanz, Pfizer), compared ....

United States , Lars Erik Kristensen , Parker Institute , Ann Rheum Dis , Erik Kristensen , Frederiksberg Hospital , North America ,

AbbVie's Skyrizi® shows long-term efficacy in psoriatic arthritis

AbbVie's Skyrizi® shows long-term efficacy in psoriatic arthritis
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Doina Cosma Roman , Lars Erik Kristensen , Abbvie Skyrizi , European Academy Of Dermatology , University Hospital , Boehringer Ingelheim , American College Of Rheumatology , Parker Institute , Clinical Development , Psoriasis Area , Severity Index , American College , European Academy , Global Assessment , Fingernail Psoriasis , Nail Psoriasis Severity Index , Active Psoriatic Arthritis , Week Results ,

AbbVie (ABBV) Reports New Data from Phase 3 Trials of SKYRIZI

AbbVie (ABBV) Reports New Data from Phase 3 Trials of SKYRIZI
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Doina Cosma Roman , Lars Erik Kristensen , European Academy Of Dermatology , Boehringer Ingelheim , American College Of Rheumatology , University Hospital In Lund , Parker Institute , Clinical Development , Psoriasis Area , Severity Index , American College , European Academy , Hybrid Congress , Global Assessment , Fingernail Psoriasis , Nail Psoriasis Severity Index ,